Related Experiment Videos
Epstein-Barr virus vectors provide prolonged robust factor IX expression in mice.
Christopher R Sclimenti1, Andrew S Neviaser, Edward J Baba
1Department of Genetics, Stanford University School of Medicine, California 94305, USA.
Biotechnology Progress
|February 8, 2003
Summary
Epstein-Barr virus (EBV) components significantly boost gene therapy vector expression in dividing cells and mouse liver. This enhances therapeutic gene delivery and prolonged expression, showing EBV
Area of Science:
- Molecular Biology
- Gene Therapy
- Virology
Background:
- Gene therapy vectors require efficient and sustained gene expression for therapeutic efficacy.
- Enhancing gene expression levels and duration is a key challenge in developing effective gene therapies.
Purpose of the Study:
- To evaluate the impact of Epstein-Barr virus (EBV) components on gene expression from vectors in dividing cells and in vivo.
- To assess the utility of EBV sequences for improving therapeutic gene expression in mouse liver.
Main Methods:
- Constructed vectors incorporating EBV elements (EBNA1, family of repeats) and human genomic DNA sequences.
- Administered naked DNA vectors via high-pressure tail vein injection in mice.
- Quantified human factor IX (hFIX) expression levels and duration in mouse liver.
Main Results:
- EBV components dramatically increased the level and duration of marker gene expression in dividing cultured cells.
- In vivo studies showed enhanced and prolonged hFIX expression in mouse liver following vector administration.
- A single dose of vector DNA yielded normal hFIX levels for 8 months, with EBV sequences increasing expression 10- to 100-fold.
Conclusions:
- EBV sequences are crucial for enhancing stable gene expression from gene therapy vectors.
- The addition of EBV components significantly improves the efficacy of in vivo gene therapy, particularly in the liver.
- These findings highlight the importance of vector design elements for successful gene therapy applications.